SG11202106700WA - Polypeptides comprising modified il-2 polypeptides and uses thereof - Google Patents

Polypeptides comprising modified il-2 polypeptides and uses thereof

Info

Publication number
SG11202106700WA
SG11202106700WA SG11202106700WA SG11202106700WA SG11202106700WA SG 11202106700W A SG11202106700W A SG 11202106700WA SG 11202106700W A SG11202106700W A SG 11202106700WA SG 11202106700W A SG11202106700W A SG 11202106700WA SG 11202106700W A SG11202106700W A SG 11202106700WA
Authority
SG
Singapore
Prior art keywords
polypeptide
antigen binding
binding domain
cancer
modified
Prior art date
Application number
SG11202106700WA
Other languages
English (en)
Inventor
John C Timmer
Brendan P Eckelman
Katelyn Mckabe Willis
Florian J Sulzmaier
Bryan R Becklund
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of SG11202106700WA publication Critical patent/SG11202106700WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11202106700WA 2019-01-07 2020-01-06 Polypeptides comprising modified il-2 polypeptides and uses thereof SG11202106700WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962789075P 2019-01-07 2019-01-07
PCT/US2020/012296 WO2020146221A1 (en) 2019-01-07 2020-01-06 Polypeptides comprising modified il-2 polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
SG11202106700WA true SG11202106700WA (en) 2021-07-29

Family

ID=69374426

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106700WA SG11202106700WA (en) 2019-01-07 2020-01-06 Polypeptides comprising modified il-2 polypeptides and uses thereof

Country Status (15)

Country Link
US (1) US20220089667A1 (cg-RX-API-DMAC7.html)
EP (1) EP3908596A1 (cg-RX-API-DMAC7.html)
JP (2) JP7594161B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210113265A (cg-RX-API-DMAC7.html)
CN (1) CN113924311A (cg-RX-API-DMAC7.html)
AR (1) AR117770A1 (cg-RX-API-DMAC7.html)
AU (2) AU2020206672B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012294A2 (cg-RX-API-DMAC7.html)
CA (1) CA3125529A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001779A1 (cg-RX-API-DMAC7.html)
IL (1) IL284633A (cg-RX-API-DMAC7.html)
MX (1) MX428580B (cg-RX-API-DMAC7.html)
SG (1) SG11202106700WA (cg-RX-API-DMAC7.html)
TW (1) TWI874345B (cg-RX-API-DMAC7.html)
WO (1) WO2020146221A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101520534B1 (ko) 2012-05-07 2015-05-21 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
IL321812A (en) 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
CN115710576A (zh) 2018-02-01 2023-02-24 Nkmax有限公司 产生天然杀伤细胞的方法和用于治疗癌症的组合物
TW202031284A (zh) 2018-11-08 2020-09-01 美商新索思股份有限公司 介白素10結合物及其用途
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
CA3148135A1 (en) 2019-08-23 2021-03-04 Carolina E. CAFFARO Il-15 conjugates and uses thereof
WO2021050554A1 (en) 2019-09-10 2021-03-18 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases
CN115916831A (zh) * 2020-06-30 2023-04-04 Gi 医诺微新 包含抗lag-3抗体和il-2的融合蛋白及其用途
EP4175979A2 (en) * 2020-07-02 2023-05-10 Inhibrx, Inc. Polypeptides comprising modified il-2 polypeptides and uses thereof
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
WO2022099090A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. Heterodimeric antibodies that bind tgfbrii
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
JP2023553216A (ja) * 2020-12-09 2023-12-20 アシャ バイオセラピューティクス,インク. 遺伝子操作細胞療法のための標的化サイトカイン構築物
CN112979782B (zh) * 2021-03-08 2023-07-18 深圳市乐土生物医药有限公司 一种多肽及其用途
CA3213751A1 (en) * 2021-03-31 2022-10-06 Ziyang Zhong Fusion proteins, pharmaceutical compositions, and therapeutic applications
TW202321283A (zh) * 2021-07-20 2023-06-01 美商英伊布里克斯公司 Cd8結合多肽及其用途
TW202309102A (zh) * 2021-07-20 2023-03-01 美商英伊布里克斯公司 靶向cd8之經修飾il-2多肽及其用途
TW202319397A (zh) * 2021-08-30 2023-05-16 美商英伊布里克斯公司 NKp46結合多肽及其用途
TW202328171A (zh) * 2021-08-30 2023-07-16 美商英伊布里克斯公司 靶向NKp46之經修飾之IL-2多肽及其用途
JP2024536840A (ja) * 2021-09-26 2024-10-08 ウーシー バイオロジクス アイルランド リミテッド Il-2バリアント及びその融合タンパク質
TW202334193A (zh) * 2022-01-05 2023-09-01 美商英伊布里克斯公司 靶向γδ T細胞之經修飾IL-2多肽及其用途
WO2024026449A2 (en) * 2022-07-28 2024-02-01 Proviva Therapeutics (Hong Kong) Limited Il-2 procytokine antibody fusion proteins
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
EP1454138B1 (en) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
CN102101885B (zh) 2010-09-01 2013-06-05 南京发士达生物科技有限公司 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
CN105440123B (zh) * 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
WO2013180200A1 (ja) * 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
PT3102595T (pt) * 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
IL304950A (en) 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
EP3402818A1 (en) * 2016-01-11 2018-11-21 Universität Zürich Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent
KR20240115933A (ko) * 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
KR20240005989A (ko) * 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
JP7148539B2 (ja) * 2017-04-03 2022-10-05 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
CA3052532A1 (en) * 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Bispecific antibodies specifically binding to pd1 and lag3
AU2018273914A1 (en) * 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
AU2018287317B2 (en) * 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof

Also Published As

Publication number Publication date
TWI874345B (zh) 2025-03-01
WO2020146221A1 (en) 2020-07-16
MX428580B (es) 2025-11-13
KR20210113265A (ko) 2021-09-15
JP7594161B2 (ja) 2024-12-04
AU2020206672B2 (en) 2025-10-02
CN113924311A (zh) 2022-01-11
JP2025013911A (ja) 2025-01-28
CA3125529A1 (en) 2020-07-16
MX2021008147A (es) 2021-08-11
TW202043259A (zh) 2020-12-01
JP2022516557A (ja) 2022-02-28
BR112021012294A2 (pt) 2021-09-08
IL284633A (en) 2021-08-31
AU2020206672A1 (en) 2021-07-15
AR117770A1 (es) 2021-08-25
AU2025283608A1 (en) 2026-01-22
CL2021001779A1 (es) 2022-03-04
EP3908596A1 (en) 2021-11-17
US20220089667A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
IL284633A (en) Polypeptides containing modified IL-2 peptides and uses thereof
IL281192A (en) Interleukin-2 polypeptide conjugates and uses thereof
IL274844A (en) IL-2 mutants and their uses
IL294052B2 (en) Fluoroalkyl oxadiazoles and their uses
IL279458A (en) Neoantigens and their uses
IL280808A (en) OX40-binding polypeptides and their uses
IL287782A (en) Cd33-binding polypeptides and uses thereof
GB2603645B (en) Polypeptides having anti-senescent effects and uses thereof
GB2600592B (en) Polypeptide and use thereof
SG11202006669RA (en) Peptides and uses thereof
IL287503A (en) Thio-semicarbazide compounds and their use
GB201819200D0 (en) Polypeptide and uses thereof
PL3630967T3 (pl) Proteaza i polipeptyd wiążący dla o-glikoprotein
IL309885A (en) Alpha-surface polypeptides and their use
GB202109082D0 (en) Polypeptides and uses thereof
EP4081235A4 (en) HEPARIN-ASSOCIATED POLYPEPTIDES AND THEIR USE
EP3947418C0 (en) PEPTIDES AND THEIR USE
IL304183A (en) Actinohibin variant polypeptides and related methods
GB201803363D0 (en) New materials and uses thereof
HK40061342A (en) Polypeptides comprising modified il-2 polypeptides and uses thereof
GB201914682D0 (en) Novel anti-cancer peptides and uses thereof
GB202018733D0 (en) Polypeptides and uses thereof
HK40068899A (en) Clec12a-binding polypeptides and uses thereof
HK40068898A (en) Cd33-binding polypeptides and uses thereof
HK40068897A (en) Cd123-binding polypeptides and uses thereof